Zanzalintinib demonstrated antitumor activity in patients with heavily pretreated, advanced clear cell RCC in a phase 1 trial. Zanzalintinib demonstrated antitumor activity in patients with heavily pretreated, advanced clear cell RCC in a phase 1 trial.
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.
High-Risk Renal Cell Carcinoma Patients Benefit from Everolimus miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.